[go: up one dir, main page]

DK1007093T3 - Behandling af forstyrrelser under anvendelse af inter-leukin-9 - Google Patents

Behandling af forstyrrelser under anvendelse af inter-leukin-9

Info

Publication number
DK1007093T3
DK1007093T3 DK97939680T DK97939680T DK1007093T3 DK 1007093 T3 DK1007093 T3 DK 1007093T3 DK 97939680 T DK97939680 T DK 97939680T DK 97939680 T DK97939680 T DK 97939680T DK 1007093 T3 DK1007093 T3 DK 1007093T3
Authority
DK
Denmark
Prior art keywords
treatment
leukin
disorders
inter
thyroiditis
Prior art date
Application number
DK97939680T
Other languages
Danish (da)
English (en)
Inventor
Jean-Christophe Renauld
Mary-Christine Many
Francois Huaux
Dominique Lison
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of DK1007093T3 publication Critical patent/DK1007093T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/206IL-9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2026IL-4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK97939680T 1996-08-30 1997-08-29 Behandling af forstyrrelser under anvendelse af inter-leukin-9 DK1007093T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/706,302 US5830454A (en) 1996-08-30 1996-08-30 Method for treating cell mediated autoimmune disorders using interleukin-9
PCT/US1997/015264 WO1998008545A1 (fr) 1996-08-30 1997-08-29 Methodes de traitement de troubles a l'aide d'interleukine-9 et de ses antagonistes

Publications (1)

Publication Number Publication Date
DK1007093T3 true DK1007093T3 (da) 2004-01-26

Family

ID=24837006

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97939680T DK1007093T3 (da) 1996-08-30 1997-08-29 Behandling af forstyrrelser under anvendelse af inter-leukin-9

Country Status (11)

Country Link
US (2) US5830454A (fr)
EP (1) EP1007093B1 (fr)
JP (1) JP2000517322A (fr)
AT (1) ATE252911T1 (fr)
AU (1) AU721908B2 (fr)
CA (1) CA2263935A1 (fr)
DE (1) DE69725897T2 (fr)
DK (1) DK1007093T3 (fr)
ES (1) ES2210569T3 (fr)
PT (1) PT1007093E (fr)
WO (1) WO1998008545A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9
AU5532098A (en) * 1996-12-20 1998-07-17 Magainin Pharmaceuticals, Inc. A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
US6328955B1 (en) * 2000-01-25 2001-12-11 Ludwig Institute For Cancer Research Method for regulating IL-10 with IL-9, and applications thereof
US6586336B2 (en) 2001-08-31 2003-07-01 Oriol, Inc. Chemical-mechanical-polishing station
AU2003226065B2 (en) * 2002-04-12 2009-02-26 Ludwig Institute For Cancer Research, Ltd Recombinant anti-interleukin-9 antibodies
GB0526000D0 (en) * 2005-12-21 2006-02-01 Ares Trading Sa Cytokine receptor
WO2012129394A2 (fr) 2011-03-22 2012-09-27 Brigham And Women's Hospital, Inc. Procédés et compositions pour le traitement du cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587302A (en) * 1988-09-19 1996-12-24 Ludwig Institute For Cancer Research T cell growth factor
US5580753A (en) * 1989-05-23 1996-12-03 Ludwig Institute For Cancer Research DNA encoding the human cytokine, interleukin-9
US5414071A (en) * 1989-05-23 1995-05-09 Genetics Institute, Inc. Human cytokine IL-9
AU7552691A (en) * 1990-03-23 1991-10-21 GSF-Institut Fur Experimentalle Hamatologie Method for enhanced growth and proliferation of mast cells
US5246701A (en) * 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
DK0846173T3 (da) * 1995-08-24 2006-01-16 Genaera Corp Anvendelse af et anti-interleukin-9-antistof til fremstilling af et lægemiddel til behandling af astma
US5830454A (en) * 1996-08-30 1998-11-03 Ludwig Institute For Cancer Research Method for treating cell mediated autoimmune disorders using interleukin-9

Also Published As

Publication number Publication date
AU721908B2 (en) 2000-07-20
WO1998008545A1 (fr) 1998-03-05
ES2210569T3 (es) 2004-07-01
EP1007093A4 (fr) 2000-11-08
AU4171297A (en) 1998-03-19
EP1007093B1 (fr) 2003-10-29
ATE252911T1 (de) 2003-11-15
US5935929A (en) 1999-08-10
DE69725897T2 (de) 2004-08-26
DE69725897D1 (de) 2003-12-04
EP1007093A1 (fr) 2000-06-14
US5830454A (en) 1998-11-03
CA2263935A1 (fr) 1998-03-05
PT1007093E (pt) 2004-03-31
JP2000517322A (ja) 2000-12-26

Similar Documents

Publication Publication Date Title
DK0880350T3 (da) Behandling af dissemineret sklerose
DE69532961D1 (de) Verwendung von porphyrine in der behandlung von multiple sklerose
ATE250412T1 (de) Muskarinische antagonisten zur behandlung von presbyopie
EA200601059A1 (ru) Сложные моноэфиры пробукола для лечения сердечно-сосудистых и воспалительных заболеваний
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
DK0739212T3 (da) Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom
PL331325A1 (en) Isobutylgabe and its derivatives useful in relieving pains
DK0750507T3 (da) Regulering af NF-kappa-B's virkning gennem proteasomet
BR9709068A (pt) Processo de tratamento.
DK1007093T3 (da) Behandling af forstyrrelser under anvendelse af inter-leukin-9
ATE233557T1 (de) Verwendung von konjugiertes linolensäure zur steigerung der aktivität von natural killer- lymphozyten
NO20002649D0 (no) Anvendelse av en blanding av diol og en alfa-hydroksysyre for behandling av hyperkeratotiske hudsykdommer
UA37199C2 (uk) Алкіламінокетони
EA199800866A1 (ru) Способ снятия боли
DK0752884T3 (da) Fremgangsmåde til behandling af auto-immune sygdomme ved anvendelse af type 1 interferoner
DE69518438D1 (de) Behandlung von übereregten nervenzellenfunktionen
KR880701687A (ko) 하수 및 타불순물 포함수를 처리하는 방법
EP0255224A3 (fr) Analogues cycliques et pontés cycliques du somatostatin utilisable comme médicaments analgésiques
EP0904094A4 (fr) Traitement de maladies osseuses au moyen d'adrenomedulline
RU95116393A (ru) Способ лечения заболеваний спинного мозга
ATE216884T1 (de) Verwendung von sulbutiamin zur behandlung von psychomotorischen oder psychointellektuellen beschwerden
RU93039401A (ru) Электрострессопсихотерапия
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin
EP0668771A4 (fr) Traitement des maladies autoimmunes par induction d'une tolerance des cellules, des tissus et des organes.
EP0444931A3 (en) Use of 3-oxygermylpropionic acid to treat and prevent diabetes-dependent autoimmune diseases